167 related articles for article (PubMed ID: 11810525)
1. Prospects for development of new antimycobacterial drugs.
Tomioka H
J Infect Chemother; 2000 Mar; 6(1):8-20. PubMed ID: 11810525
[TBL] [Abstract][Full Text] [Related]
2. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
3. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
4. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Sato K; Tomioka H; Akaki T; Kawahara S
Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
[TBL] [Abstract][Full Text] [Related]
6. [Preclinical study of therapeutic agents used against Mycobacterium avium complex infections--with special reference to new macrolides and new quinolones].
Tomioka H; Sato K; Saito H
Kekkaku; 1996 Sep; 71(9):531-5. PubMed ID: 8999135
[No Abstract] [Full Text] [Related]
7. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
8. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
9. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
Pellegrin I; Maugein J; Lapeyre C; Barbeau P; Leng B; Pellegrin JL
J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.
Tomioka H; Saito H; Fujii K; Sato K; Hidaka T
Antimicrob Agents Chemother; 1993 Jan; 37(1):67-70. PubMed ID: 8431020
[TBL] [Abstract][Full Text] [Related]
11. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
12. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
[TBL] [Abstract][Full Text] [Related]
13. Antimycobacterial synergism of clarithromycin and rifabutin.
Ghebremichael S; Svenson SB; Källenius G; Hoffner SE
Scand J Infect Dis; 1996; 28(4):387-90. PubMed ID: 8893404
[TBL] [Abstract][Full Text] [Related]
14. Antimycobacterial drugs.
Heifets LB
Semin Respir Infect; 1994 Jun; 9(2):84-103. PubMed ID: 7973175
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of quinolones and macrolides against mycobacteria.
Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Akaki T; Kajitani H; Kawahara S; Sakatani M
Antimicrob Agents Chemother; 1999 Dec; 43(12):3001-4. PubMed ID: 10582897
[TBL] [Abstract][Full Text] [Related]
18. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
Gevaudan MJ; Bollet C; Mallet MN; de Lamballerie X; Sambuc R; de Micco P
Pathol Biol (Paris); 1992 May; 40(5):443-9. PubMed ID: 1323093
[TBL] [Abstract][Full Text] [Related]
19. [Antimycobacterial activities of rifamycin derivatives].
Kuze F
Kekkaku; 1991 Oct; 66(10):679-85. PubMed ID: 1960916
[TBL] [Abstract][Full Text] [Related]
20. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
Tomioka H; Sato K; Sano C; Sano K; Shimizu T
Antimicrob Agents Chemother; 2002 Feb; 46(2):519-21. PubMed ID: 11796367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
